HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on BioXcel Therapeutics (NASDAQ:BTAI) and maintained an $11 price target.
September 08, 2023 | 10:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioXcel Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $11.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for BioXcel Therapeutics. This could potentially attract investors and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100